ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

ONC Oncimmune Holdings Plc

21.20
0.20 (0.95%)
28 Mar 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Oncimmune Holdings Plc LSE:ONC London Ordinary Share GB00BYQ94H38 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.20 0.95% 21.20 20.60 22.00 21.00 21.00 21.00 12,949 16:35:29
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Medical Laboratories 1.47M -6.15M -0.0830 -2.53 15.57M

Oncimmune Holdings PLC Distribution agreement signed for Iran (6285W)

16/11/2017 7:00am

UK Regulatory


Oncimmune (LSE:ONC)
Historical Stock Chart


From Mar 2019 to Mar 2024

Click Here for more Oncimmune Charts.

TIDMONC

RNS Number : 6285W

Oncimmune Holdings PLC

16 November 2017

16 November 2017

Oncimmune Holdings plc

("Oncimmune" or the "Company")

Distribution agreement signed for EarlyCDT(R)-Lung Kit in Iran

Agreement for screening and indeterminate pulmonary nodule applications with minimum sales commitment of approximately GBP1.1m

Nottingham, UK - 9 November 2017: Oncimmune Holdings plc (AIM: ONC.L), a leading early cancer detection company developing and commercialising its proprietary EarlyCDT(R) platform technology, today announces it has signed an exclusive agreement for distribution of its EarlyCDT(R)-Lung test in Iran with Tarvand Sina Tajhiz Co., an Iranian provider of test services and kits to the medical community.

The agreement allows for the sale of the CE marked EarlyCDT(R)-Lung kit as a screening test and for the risk assessment of indeterminate pulmonary nodules. The agreement is for an initial term of three years and includes minimum sales commitments of GBP1.1 million over the term of the contract. First sales are expected to commence in the second half of 2018.

Geoffrey Hamilton-Fairley, CEO of Oncimmune, commented: "This distribution agreement is our seventh in the Asia Pacific region and now brings the minimum sales commitment in this region to approximately GBP7.6 million over the next five years. In the coming months we expect to sign a number of further agreements in the region, and beyond, as we continue to deliver on our strategy of generating revenues from our platform technology through multiple products, regions and partners."

For further information:

Oncimmune Holdings plc

Geoffrey Hamilton-Fairley, Chief Executive Officer

contact@oncimmune.co.uk

Zeus Capital Limited (Nominated Advisor and Broker)

Giles Balleny, Hugh Kingsmill Moore

+44 (0) 203 829 5000

Media enquiries:

Consilium Strategic Communications

Chris Gardner, Matthew Neal, Lindsey Neville

oncimmune@consilium-comms.com

+44 (0) 20 3709 5708

About Oncimmune

Oncimmune is a leading early cancer detection company developing and commercialising its proprietary EarlyCDT(R) platform technology. Oncimmune has pioneered the development of autoantibody tests that can detect cancer up to four years earlier than other methods and can be applied to a very wide range of solid tumour types. The Company's first product, EarlyCDT(R)-Lung, was launched in 2012, as a CLIA test in the USA and since then over 150,000 commercial tests have been sold. EarlyCDT(R)-Lung is available through physicians in the US and also privately in the UK and other regions. EarlyCDT(R)-Lung is being used in the largest ever randomised trial for the early detection of lung cancer using biomarkers, the National Health Service (NHS) Scotland ECLS study of 12,210 high-risk smokers. EarlyCDT(R) tests for liver and ovarian cancer are in development.

Oncimmune, headquartered in Nottingham, United Kingdom with testing facilities in the US, joined AIM in May 2016 under the ticker ONC.L. For more information, visit www.oncimmune.com

This information is provided by RNS

The company news service from the London Stock Exchange

END

AGRGGGAWGUPMGQA

(END) Dow Jones Newswires

November 16, 2017 02:00 ET (07:00 GMT)

1 Year Oncimmune Chart

1 Year Oncimmune Chart

1 Month Oncimmune Chart

1 Month Oncimmune Chart

Your Recent History

Delayed Upgrade Clock